A Study Investigating a Short Duration of Ledipasvir-Sofosbuvir Therapy (8 weeks) in Hepatitis C-Virus (HCV) Genotype 1a Patients with HIV Co-Infection

Trial Profile

A Study Investigating a Short Duration of Ledipasvir-Sofosbuvir Therapy (8 weeks) in Hepatitis C-Virus (HCV) Genotype 1a Patients with HIV Co-Infection

Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Jan 2018

At a glance

  • Drugs Ledipasvir (Primary) ; Sofosbuvir (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top